Nuvalent Shares Updated Data On ALK And ROS1 Inhibitors
09 Sep 2024 //
PR NEWSWIRE
Nuvalent To Present ROS1 And ALK Inhibitor Data At ESMO 2024
16 Jul 2024 //
PR NEWSWIRE
Nuvalent Presents New Preclinical Data of Zidesamtinib at AACR
08 Apr 2024 //
PR NEWSWIRE
Nuvalent to Present New Preclinical Data on NVL-330, and zidesamtinib
05 Mar 2024 //
PR NEWSWIRE